STIFEL 2026: Cullinan Therapeutics' CEO Nadim Ahmed gives an overview of the progress of the company's T-cell engagers in autoimmune and oncology (and more)

0:00-11:24

He goes over a partner's BCMA data that was just presented this weekend at ACR in lupus, and previews a key CD19 update that Cullinan will be providing investors in December. Plus, he comments on zipalertinib, which is in front of FDA now in two lines of therapy.

B-

BiotechTV - News

@biotechtvnews

#cullinantherapeuticsceo #cellengagers #autoimmune #lifesciences

The Nile